Abstract: Methods for identifying compounds that are inhibitors or are likely to be inhibitors of amyloid protein aggregation, as well as three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation utilized in the methods, are described. Means for creating the three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation are also described.

Abstract: Compounds or pharmaceutical acceptable salts thereof of Formula (I), in which RM have the meaning described herein and pharmaceutical compositions thereof useful as antimicrobial and/or adjuvant:

Abstract: Compounds or pharmaceutical acceptable salts thereof of Formula (I), in which RM have the meaning described herein and pharmaceutical compositions thereof useful as antimicrobial and/or adjuvant:

Abstract: Methods for identifying compounds that are inhibitors or are likely to be inhibitors of amyloid protein aggregation, as well as three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation utilized in the methods, are described. Means for creating the three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation are also described.

Abstract: In general, among other things, compounds of Formula I are provided: in which R11 is e.g., 4-(pyrrolidin-1-yl)piperidin-1-yl, N-methyl-3-(pyrrolidin-1-yl)propan-1-amino, N1,N1,N3-trimethylpropane-1,3-diamino, N,N-dimethylpiperidin-4-amino, 3-(pyrrolidin-1-ylmethyl)azetidin-1-yl, 3-(pyrrolidin-1-ylmethanon)azetidin-1-yl, or 3-(morpholin-1-ylmethyl)azetidin-1-yl; R13 is, e.g., phenyl optionally substituted with one or more substituents; and R12 and R14 are each independently hydrogen or alkyl. Methods of treatment are also provided.

Abstract: In general, among other things, compounds of Formula I are provided: in which R11 is e.g., 4-(pyrrolidin-1-yl)piperidin-1-yl, N-methyl-3-(pyrrolidin-1-yl)propan-1-amino, N1,N1,N3-trimethylpropane-1,3-diamino, N,N-dimethylpiperidin-4-amino, 3-(pyrrolidin-1-ylmethyl)azetidin-1-yl, 3-(pyrrolidin-1-ylmethanon)azetidin-1-yl, or 3-(morpholin-1-ylmethyl)azetidin-1-yl; R13 is, e.g., phenyl optionally substituted with one or more substituents; and R12 and R14 are each independently hydrogen or alkyl. Methods of treatment are also provided.

Abstract: Methods for identifying compounds that are inhibitors or are likely to be inhibitors of amyloid protein aggregation, as well as three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation utilized in the methods, are described. Means for creating the three-dimensional, non-crystallographic models (i.e. “pseudo-crystal structures”) of amyloid aggregation are also described.

Abstract: In general, among other things, compounds of Formula I are provided: in which R11 is selected from the group consisting of benzylamino, N-methylbenzylamino, morpholino, thiomorpholino, pyrrolidino, etc.; R13 is selected from the group consisting of 3-(1-ethanol-2-yl)phenyl, 3-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, 2-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, etc.; and R12 and R14 are each independently hydrogen or alkyl. Methods of treatment are also provided.

Abstract: In general, among other things, compounds of Formula I are provided: in which R11 is selected from the group consisting of benzylamino, N-methylbenzylamino, morpholino, thiomorpholino, pyrrolidino, etc.; R13 is selected from the group consisting of 3-(1-ethanol-2-yl)phenyl, 3-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, 2-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, etc.; and R12 and R14 are each independently hydrogen or alkyl. Methods of treatment are also provided.

Abstract: In general, among other things, compounds of Formula I are provided: in which R11 is selected from the group consisting of benzylamino, N-methylbenzylamino, morpholino, thiomorpholino, pyrrolidino, etc.; R13 is selected from the group consisting of 3-(1-ethanol-2-yl)phenyl, 3-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, 2-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, etc.; and R12 and R14 are each independently hydrogen or alkyl. Methods of treatment are also provided.

Abstract: Among other things, in general, antimicrobial and/or adjuvant compounds are provided according to Formula Ia: (Ia) in which E and R1-11 have the meanings described herein; and prodrugs and pharmaceutically acceptable salts thereof. Other formulae and methods of use are also provided.

Abstract: Among other things, in general, antimicrobial and/or adjuvant compounds are provided according to Formula Ia: (Ia) in which E and R1-11 have the meanings described herein; and prodrugs and pharmaceutically acceptable salts thereof. Other formulae and methods of use are also provided.

Abstract: Anti-amyloid compounds are provided along with methods of use thereof.

Abstract: The present invention is directed to compounds that inhibit amyloid aggregation and methods of treatment therewith.

Abstract: The present invention is directed to compounds that inhibit amyloid aggregation and methods of treatment there-with.

Abstract: The present invention provides for therapies characterized in part by co-administration or combination of antibiotic agents with medicinal compositions comprising as the pro-antibiotic active ingredient either a compound represented by a formula [I] or a pharmaceutically acceptable composite thereof; [wherein X represents oxygen, sulfur, NH, or N-alkyl; R1 and R2 represent hydrogen, tetrazole, or alkyltetrazole, respectively (with the restriction that if R1 is not hydrogen, R2 must be, and vice versa); R3 represents e.g., benzyl, phenyl optionally substituted, biphenyl, napthyl, N-phenylcarboxamido, etc., R4 represents e.g. carboxylic acid, or its alkyl esters, or a bioisoteric equivalent thereof, etc.; R5 represents e.g. hydrogen, carboxylic acid, etc.] in particular, medicine which is useful as therapeutic and/or protective drugs for infectious and/or inflammatory diseases. Other relevant compounds are also provided.